These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9450187)

  • 1. Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?
    Bar-Sade RB; Theodor L; Gak E; Kruglikova A; Hirsch-Yechezkel G; Modan B; Kuperstein G; Seligsohn U; Rechavi G; Friedman E
    Eur J Hum Genet; 1997; 5(6):413-6. PubMed ID: 9450187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
    Bar-Sade RB; Kruglikova A; Modan B; Gak E; Hirsh-Yechezkel G; Theodor L; Novikov I; Gershoni-Baruch R; Risel S; Papa MZ; Ben-Baruch G; Friedman E
    Hum Mol Genet; 1998 May; 7(5):801-5. PubMed ID: 9536083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients.
    Díez O; Osorio A; Robledo M; Barroso A; Domènech M; Cortés J; Albertos J; Sanz J; Brunet J; SanRomán JM; Alonso MC; Baiget M; Benítez J
    Br J Cancer; 1999 Mar; 79(7-8):1302-3. PubMed ID: 10098775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
    Foulkes WD; Wong N; Brunet JS; Bégin LR; Zhang JC; Martinez JJ; Rozen F; Tonin PN; Narod SA; Karp SE; Pollak MN
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2465-9. PubMed ID: 9815648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
    Gal I; Kimmel G; Gershoni-Baruch R; Papa MZ; Dagan E; Shamir R; Friedman E
    Eur J Cancer; 2006 May; 42(8):1129-34. PubMed ID: 16624550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
    Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.
    Quintana-Murci L; Gal I; Bakhan T; Quach H; Sayar SH; Shiri-Sverdlov R; Baruch RG; McElreavey K; Dagan E; Narod S; Friedman E
    Fam Cancer; 2005; 4(2):85-8. PubMed ID: 15951957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.